GSK Jumps On Hiked 2025 Outlook, But CEO Remains 'Very Cautious' About Vaccines

Core Insights - GSK reported strong third-quarter earnings, with earnings per share of approximately 73 cents and sales of $11.35 billion, surpassing forecasts of 61 cents and $10.93 billion respectively [1][2] - The company raised its full-year sales growth outlook to 6% to 7%, up from a previous range of 3% to 5%, and core earnings per share growth guidance to 10% to 12%, increased from 6% to 8% [2] Financial Performance - GSK's earnings per share increased from 65 cents in the same period last year, with sales rising from $10.42 billion [1] - Analysts had projected earnings per share of $2.18 on sales of $42.68 billion, reflecting a respective increase of 10% and 9% [2] Market Reaction - Following the earnings report and raised guidance, GSK's stock rose more than 3% to $45.11 [2]